CLRBCellectar Biosciences, Inc.Not started yet
Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
Waldenstrom Macroglobulinaemia · Waldenstrom Macroglobulinemia · Waldenstrom's Macroglobulinaemia Refractory · Waldenstrom Macroglobulinemia With Nodal Disease · Waldenstrom's Macroglobulinemia Recurrent
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 219 (planned)
- Started
- Dec 2026
- Main results expected
- Jan 2032
- Fully finished
- Jan 2035
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Superiority of progression free survival (PFS)
Measured over: From baseline randomization through study completion of progressive disease, or death due to any reason (whichever status is recorded first).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07766421 · record last updated 2026-08-14 · checked 2026-11-09 15:47 UTC